Coherus Oncology (CHRS) Invested Capital (2012 - 2026)

Coherus Oncology has disclosed Invested Capital across 15 years of filings, most recently posting $78.6 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $78.6 million, up 150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.6 million (up 150.0% YoY), and the FY2025 annual result was $61.0 million, up 151.55% from the prior year.
• Invested Capital came in at $78.6 million for Q1 2026 at Coherus Oncology, up from $61.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $119.8 million in Q2 2025 to a low of -$196.3 million in Q1 2023.
• The 5-year median for Invested Capital is -$81.8 million (2024), against an average of -$64.7 million.
• Across the five-year window, Invested Capital tumbled 1662.84% in 2023 and surged 259.97% in 2025, its largest moves.
• Coherus Oncology's Invested Capital stood at -$137.4 million in 2022, then sank by 38.36% to -$190.1 million in 2023, then jumped by 37.74% to -$118.4 million in 2024, then surged by 151.55% to $61.0 million in 2025, then gained by 28.86% to $78.6 million in 2026.
• The last three Invested Capital figures came in at $78.6 million (Q1 2026), $61.0 million (Q4 2025), and $87.8 million (Q3 2025), per Business Quant data.